ArticleJournal of the American Heart Association2026
METTL3-m6A-SLC25A11 Axis Promotes Chronic Hypoxia-Induced Cardiomyocyte Ferroptosis.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined machine learning identification and experimental validation of NDUFS8 and SUCLG1 as potential biomarkers for mechanical asphyxia.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hypoxia is commonly associated with various cardiovascular diseases, with cardiomyocyte death being the most frequently observed alteration. Mitochondrial dysfunction is another consequence seen in the hypoxic heart. However, the mechanistic linkage between mitochondrial dysfunction and cardiomyocyte death in the hypoxic heart remains unclear. Solute carrier family 25 member 11 (SLC25A11) is essential for mitochondrial function via transporting glutathione to mitochondria and is possibly involved in ferroptosis. However, the role of SLC25A11 in chronic hypoxia-induced cardiomyocyte ferroptosis remains unknown.
methodsSLC25A11 overexpression and short hairpin RNA vector were constructed and introduced into the AC16 cardiomyocytes and human induced pluripotent stem cell-derived cardiomyocytes exposed to chronic hypoxia, and the cell viability, mitochondrial function, and ferroptosis were evaluated. Myocardial injury and cardiac function were also assessed in hypoxic mouse models.
resultsOur findings reveal that chronic hypoxia induced ferroptosis and mitochondrial dysfunction and decreased cell viability and SLC25A11 expression. SLC25A11 overexpression inhibited chronic hypoxia-induced ferroptosis and mitochondrial dysfunction. SLC25A11 silencing-induced ferroptosis is reversed by iron chelator deferoxamine. Chronic hypoxia-induced increased the N6-methyladenosine (m6A) level of SLC25A11 3'UTR and decreased expression of SLC25A11 were reversed by methyltransferase-like 3 inhibitor STM2457. m6A-binding protein YTH domain family 2 binds to the SLC25A11 3'UTR. STM2457 reversed chronic hypoxia-induced cardiomyocyte ferroptosis and mitochondrial dysfunction, while SLC25A11 knockdown abolished the effects of STM2457. The ameliorative effect of STM2457 in cardiomyocyte injury was proved in the hypoxia mouse model.
conclusionsThis study is the first to demonstrate the protective effect of methyltransferase-like 3 inhibition, via SLC25A11 m6A modification, against chronic hypoxia-induced cardiomyocyte ferroptosis and reveals the possibility that inhibiting activation of methyltransferase-like 3-m6A-SLC25A11 may provide cardioprotective therapy for chronic hypoxia-induced cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.